Microplastics now show up in human blood, placental tissue, atherosclerotic plaque, and the brain. The early literature points toward chronic inflammation, endocrine disruption, and metabolic stress as likely consequences. At Elora Therapeutics, we are building engineered PET-degrading enzymes designed to operate inside the body, drawing on the natural PETase and MHETase enzymes first characterized in Ideonella sakaiensis. It is frontier science with no playbook, and a protein-engineering problem at its heart; designing enzymes that are stable, selective, and safe in vivo.